Video

Should Men with Prior CVD be Treated Preferentially with a GnRH Antagonist?

Dr Higano provides a timeline review of safety results for GnH agonists and GnRH antagonists including the recent prospective phase 3 PRONOUNCE study for prostate cancer patients with pre-existing CV disease, followed by closing thoughts on this video series.

January 2023 AbbVie Inc. Company Confidential

Related Videos
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
Michael Jenson, PA-C, answers a question during a Zoom video interview
Couple talking with doctor | Image Credit: © Chinnapong - stock.adobe.com
Andrew C. Peterson, MD, MPH, answers a question during a Zoom interview
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
Oliver Sartor, MD, is featured in this series.
Man talking with doctor, who is taking notes on a clipboard | Image Credit: © DragonImages - stock.adobe.com
Oliver Sartor, MD, is featured in this series.
1 KOL is featured in this series.
Related Content
FDA reports Urgent Field Safety Notice on mini PCNL sheath
December 20th 2024

FDA reports Urgent Field Safety Notice on mini PCNL sheath

Hannah Clarke
The alert was issued to clarify that the devices should not be used for suction and irrigation.
Dr. Murphy on increasing diversity in cancer clinical trials
February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff
In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
Agreement reached for public reimbursement of Pluvicto in Canada
December 17th 2024

Agreement reached for public reimbursement of Pluvicto in Canada

Hannah Clarke
Pluvicto was approved by Health Canada in August 2022.
Dr. Schwen on focal therapies for prostate cancer
January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic
Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.
Adding CAN-2409 to radiation improves DFS in localized prostate cancer
December 13th 2024

Adding CAN-2409 to radiation improves DFS in localized prostate cancer

Hannah Clarke
“If approved, this approach has the potential to transform the treatment paradigm in prostate cancer, offering patients with localized disease an effective treatment option that may reduce the risk of disease recurrence," says Glen Gejerman, MD, MBA.
Published data show noninferior treatment-free survival with HIFU vs RP
December 12th 2024

Published data show noninferior treatment-free survival with HIFU vs RP

Hannah Clarke
Specifically, 90% of patients in the HIFU arm vs 86% of patients in the radical prostatectomy arm were free from subsequent definitive treatment at 30 months.
© 2024 MJH Life Sciences

All rights reserved.